Midazolam

Midazolam is a substance defined by speed and amnesia. Within minutes of administration -- sometimes before you have finished processing the fact that you have taken it -- the effects arrive with a startling swiftness. A thick wave of sedation rolls through consciousness, and the world immediately begins to lose its edges. Vision softens, sounds become distant and muffled, and there is a sudden, heavy warmth that descends over the body like a weighted blanket dropped from above. The onset is so rapid that the transition from sober to deeply sedated can feel less like a gradual shift and more like a light switch being dimmed.

The come-up, such as it is, compresses into the first five to ten minutes. The sedation deepens quickly, and the amnestic properties begin almost immediately -- the hallmark feature that has made midazolam the standard for procedural sedation. Memory stops being recorded with any fidelity; events occur but leave no trace, like footprints on a beach being erased by waves as they form. There is a paradoxical quality to this: you may continue to speak, respond to questions, even follow simple instructions, but none of this will be accessible to recall afterward. The body relaxes completely, muscles going slack with a thoroughness that borders on the pharmacological definition of limp.

At the peak, consciousness becomes a thin, transparent thing. You are present in only the most technical sense -- the body occupies space, the eyes may be open, but the subjective experience of being has been reduced to its bare minimum. There is no anxiety, no discomfort, no engagement with the world in any meaningful way. Time does not distort so much as it ceases to be tracked. If there is euphoria, it is the euphoria of complete surrender -- a letting go so total that there is nothing left to hold on to. The amnestic curtain is drawn completely, and the peak exists only for those witnessing it, never for the person experiencing it.

The offset is a slow, groggy emergence. Consciousness reassembles itself over thirty to sixty minutes, and the first clear awareness is often a sense of confusion about how much time has passed and what has occurred. There is a residual sedation that may persist for an hour or two, and the amnestic gaps are clean and permanent. The overall experience, insofar as it can be called an experience, is one of pharmacological disappearance -- a brief, total vacation from the demands of being conscious.

Midazolam is a short-acting benzodiazepine in adults with an elimination half-life of 1.5–2.5 hours. Midazolam is metabolised into an active metabolite alpha1-hydroxymidazolam. However, the active metabolite of midazolam is minor and contributes to only 10 percent of biological activity of midazolam. Midazolam is poorly absorbed orally, with only 50 percent of the drug reaching the bloodstream.

Midazolam is metabolized by cytochrome P450 (CYP) enzymes and by glucuronide conjugation. The therapeutic and adverse effects of midazolam are a result of its effects on the GABAA receptors; midazolam does not activate GABAA receptors directly but, as with other benzodiazepines, it enhances the effect of the neurotransmitter GABA on the GABAA receptors (↑ frequency of Cl− channel opening) resulting in neural inhibition. Almost all of the pharmacokinetic properties can be explained by the actions of benzodiazepines on GABAA receptors.

People experiencing amnesia as a side effect of midazolam are generally unaware their memory is impaired, unless they had previously known it as a side effect.Long-term use of benzodiazepines has been associated with long-lasting deficits of memory, and show only partial recovery six months after stopping benzodiazepines. It is unclear whether full recovery occurs after longer periods of abstinence. Benzodiazepines can cause or worsen depression. Paradoxical excitement occasionally occurs with benzodiazepines, including a worsening of seizures.

Benzodiazepine dependence occurs in about one-third of individuals who are treated with benzodiazepines for longer than 4 weeks, which typically results in tolerance and benzodiazepine withdrawal syndrome when the dose is reduced too rapidly. Midazolam infusions may induce tolerance and a withdrawal syndrome in a matter of days.

The risk factors for dependence include dependent personality, use of a benzodiazepine that is short-acting, high potency and long-term use of benzodiazepines. Withdrawal symptoms from midazolam can range from insomnia and anxiety to seizures and psychosis. Withdrawal symptoms can sometimes resemble a person's underlying condition.

Gradual reduction of midazolam after regular use can minimise withdrawal and rebound effects. Tolerance and the resultant withdrawal syndrome may be due to receptor down-regulation and GABAA receptor alterations in gene expression, which causes long-term changes in the function of the GABAergic neuronal system.

• Overdose

A midazolam overdose is considered a medical emergency and generally requires the immediate attention of medical personnel. Benzodiazepine overdose in healthy individuals is rarely life-threatening with proper medical support; however, the toxicity of benzodiazepines increases when they are combined with other CNS depressants such as alcohol, opioids, or tricyclic antidepressants. The toxicity of benzodiazepine overdose and risk of death is also increased in the elderly and those with obstructive pulmonary disease or when used intravenously.

Protease inhibitors, nefazodone, sertraline, grapefruit, fluoxetine, erythromycin, diltiazem, clarithromycin inhibit the metabolism of midazolam, leading to a prolonged action. St John's wort, rifapentine, rifampin, rifabutin, phenytoin enhance the metabolism of midazolam leading to a reduced action. Sedating antidepressants, antiepileptic drugs such as phenobarbital, phenytoin and carbamazepine, sedative antihistamines, opioids, antipsychotics and alcohol enhance the sedative effects of midazolam.

St John's wort decreases the blood levels of midazolam. Grapefruit juice reduces intestinal 3A4 and results in less metabolism and higher plasma concentrations.

• Sweden: Midazolam is a prescription only medication.

• Brazil: Midazolam is a prescription only medication.

• United States: Midazolam is a Schedule IV substance.

• Responsible use

• Depressants

• Benzodiazepines

• Midazolam (Wikipedia)

• Midazolam (Isomer Design)

• Midazolam (DrugBank)

• Midazolam (Drugs.com)

FORCETOC INDEX

Midazolam belongs to the depressant class of psychoactive substances, which encompasses a diverse range of compounds that reduce central nervous system activity.

The history of CNS depressants in medicine stretches back millennia, from the ancient use of alcohol and opium to the development of barbiturates in the early 1900s and benzodiazepines in the 1960s. Each generation of depressant drugs was initially heralded as safer than its predecessors, only for patterns of dependence and misuse to emerge with wider use.

The development of benzodiazepines represented a significant improvement in the therapeutic index over barbiturates, though concerns about dependence and long-term cognitive effects have moderated initial enthusiasm. Newer GABAergic compounds, including the Z-drugs and various research chemicals, continue this pattern of iterative development.

Midazolam is situated within this evolving pharmacological landscape, with its own specific history of development, clinical application, and patterns of use.